Antongiulio Faggiano


Titolo Pubblicato in Anno
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas. results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial THE LANCET 2024
Short fasting test as a reliable and effective tool to diagnose insulinoma ENDOCRINE 2024
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group CANCER TREATMENT REVIEWS 2024
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force JOURNAL OF NEUROENDOCRINOLOGY 2024
Rachel score: a nomogram model for predicting the prognosis of lung neuroendocrine tumors JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION 2024
Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety SEMINARS IN NUCLEAR MEDICINE 2024
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION 2024
Correction to: Neuroendocrine neoplasms in~the~context of~inherited tumor syndromes: a~reappraisal focused on~targeted therapies (Journal of Endocrinological Investigation, (2022), 10.1007/s40618-022-01905-4) JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION 2023
The effects of non-andrological medications on erectile dysfunction: a large single-center retrospective study JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION 2023
Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2023
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study NEUROENDOCRINOLOGY 2023
Recurrence-Free Survival in Early and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Tumor Resection JOURNAL OF PERSONALIZED MEDICINE 2023
Vitamin D and Bone Metabolism in Adult Patients with Neurofibromatosis Type 1 METABOLITES 2023
Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists CANCER TREATMENT REVIEWS 2023
Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs CANCERS 2023
Management of functional pancreatic neuroendocrine neoplasms CURRENT TREATMENT OPTIONS IN ONCOLOGY 2023
Women with type 1 diabetes gain more weight during pregnancy compared to age-matched healthy women despite a healthier diet: a prospective case-control observational study HORMONES 2023
Diabetes and erectile dysfunction: The relationships with health literacy, treatment adherence, unrealistic optimism, and glycaemic control DIABETES/METABOLISM RESEARCH AND REVIEWS 2023
MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocrinology (SIE)/Italian Society of Pharmacology (SIF) multidisciplinary critical view ESMO OPEN 2023
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastro entero pancreatic neuroendocrine tumors: alternatives to RECIST JOURNAL OF NEUROENDOCRINOLOGY 2023


  • LS2_1
  • LS2_14
  • LS4_4
  • LS4_9
  • LS4_12
  • LS7_4
  • LS7_8
  • LS7_10
  • LS7_14


  • Life-science technologies & biotechnologies

Interessi di ricerca

La principale area di ricerca sono è l'endocrinologia oncologica con numerose pubblicazioni e progetti clinici e traslazionali sulle neoplasie neuroendocrine, le neoplasie tiroidee, l'iperparatiroidismo, i tumori ipofisari, i feocromocitomi e paragangliomi, le sindromi neoplastiche genetiche multiendocrine. In tale ambito l'interesse di ricerca va dagli studi epidemiologici e di valutazione di fattori prognostici clinici e molecolari, studi sul ruolo della sindrome metabolica, della nutrizione e dei fatoori ambientali sulle neoplasie endocrine e neuroendocrine, studi genetici (ricerca nuove mutazioni, VUS, screening genetico, analisi NGS), studi diagnostici sulla diagnosi biochimica e ormonale e la diagnosi di imaging, studi terapeutici sull'efficacia e tossicità di farmaci biologici come analoghi della somatostatina, dopamino-agonisti, inibitori di mTOR, inibitori tirosino-chinasici. Più di recente interesse per l'andrologia, i tumori testicolari e le malattie genetiche della sfera andrologica


neuroendocrine tumors (NETs)
Neuroendocrine neoplasms
multiple endocrine neoplasia type 1
Multiple Endocrine Neoplasia Type 2a/drug therapy
medullary thyroid cancer
endocrine disrupting chemicals
Endocrine Gland Neoplasms
Endocrine function
andrological health

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma